Abstract: Monkeypox is a self-limiting zoonotic viral disease and causes smallpox-like symptoms. The disease has a case fatality ratio of 3–6% and, recently, a multi-country outbreak of the disease has occurred. The currently available vaccines that have provided immunization against monkeypox are classified as live attenuated vaccinia virus-based vaccines, which pose challenges of safety and efficacy in chronic infections. In this study, we have used an immunoinformatics-aided design of a multi-epitope vaccine (MEV) candidate by targeting monkeypox virus (MPXV) glycoproteins and membrane proteins. From these proteins, seven epitopes (two T-helper cell epitopes, four T-cytotoxic cell epitopes and one linear B cell epitope) were finally selected and predicted as antigenic, non-allergic, interferon-γ activating and non-toxic. These epitopes were linked to adjuvants to design a non-allergic and antigenic candidate MPXV-MEV. Further, molecular docking and molecular dynamics simulations predicted stable interactions between predicted MEV and human receptor TLR5. Finally, the immune-simulation analysis showed that the candidate MPXV-MEV could elicit a human immune response. The results obtained from these in silico experiments are promising but require further validation through additional in vivo experiments.

Keywords: monkeypox; monkeypox virus; immunoinformatics; epitope-based vaccine; orthopoxvirus; reverse vaccinology

1. Introduction

Monkeypox is a zoonotic viral infection with a 3–6% fatality rate and is caused by the monkeypox virus (MPXV) [1,2]. Two subfamilies of the MPXV, namely West African and Central African, are known but the mortality rate is observed to be higher with the Central African subfamily of the virus [2]. Humans can be exposed to the MPXV through respiratory droplets, body fluids, lesions of the infected person, interactions with infected animals and contact with virus-contaminated fomites [3,4]. MPXV was isolated for the first time in Denmark from the lesions of infected cynomolgus macaques, monkeys imported from Singapore in 1958 [5]. Human infection with MPXV was first observed in an infant with smallpox-like symptoms [5]. Since then, human cases of monkeypox have been recorded in 11 Western and Central African countries such as Nigeria, Sierra Leone, and...
the Central African Republic [5–7]. The human transmission of MPXV could also be attributed to the end of the smallpox vaccination program, which provided cross-immunity against MPXV [8]. Recently, there has been a multi-country outbreak of human monkeypox cases [9].

Although monkeypox is self-limiting, people with comorbidities and compromised immunity, pregnant women, and the pediatric population are at higher risk. The protection from MPXV in humans could be provided by the smallpox vaccine [5]. However, the smallpox vaccination program has been stopped after the eradication of smallpox in 1980 [10]. ACAM2000, a live vaccinia virus vaccine, has been advised by the Advisory Committee on Immunization Practices (USA) for the vaccination of the laboratory personnel that routinely handle human infectious orthopoxviruses such as monkeypox, cowpox and variola viruses, and the medical personnel dealing with patients infected with vaccinia virus [11]. However, ACAM2000 has been reported to have side effects such as post-vaccinal encephalitis, eczema vaccinatum and progressive vaccinia [11]. The use of ACAM2000 also poses safety concerns since it contains live vaccinia virus [11]. Further, many antivirals which have been employed for the treatment of orthopoxvirus, for instance, tecovirimat (SIGA Technologies, New York, NY, USA), inhibit viral DNA replication [12,13]. Tecovirimat is effective against monkeypox, variola, cowpox and vaccinia viruses in several animal models [12,13]. As per the guidelines from the Center for Disease Control and Prevention (CDC), USA, tecovirimat could be used for the treatment of monkeypox in an outbreak. Similarly, cidofir and vaccinia immune globulin (VIG), which are approved by the FDA for cytomegalo and vaccinia viruses, respectively, could also be used for monkeypox during an outbreak [14,15]. Apart from the drugs approved by the FDA, several approaches are being explored to intervene in the growth and outspread of MPXV, for instance, human interferon-β is found to inhibit MPXV production and dissemination in mammalian cell lines [16]. Intriguingly, vaccinia virus LC16m8, which lacks the expression of the B5R membrane protein, protects against MPXV after immunization in cynomolgus monkeys [17]. Similarly, another attenuated vaccinia virus, NYCBH, after deletion of an immune evasion gene, is found to be effective in cynomolgus monkeys against monkeypox virus [18]. Nevertheless, there are no specific vaccines or antivirals available for the monkeypox infection in humans. The SARS-CoV-2 pandemic has already created the vigilance among scientific community to prepare beforehand for any highly contagious human viruses. Thus, it is of the utmost important to find novel strategies for developing potential therapies for monkeypox virus to prevent any such calamity in the future.

Interestingly, with the recent advances in the field of immunoinformatics, the pace of the vaccine development process has been relatively accelerated [19–24]. Based on immunoinformatics, we have identified different epitopes specifically for targeting multiple serotypes of the dengue virus [24]. Further extending this exciting computational-based vaccine design approach, our team has recently designed a vaccine for canine circovirus [24,25]. In the present study, we targeted different glycoproteins and membrane proteins (Table 1) of MPXV to identify immunogenic B-cell and CD4⁺ and CD8⁺ T-cell epitopes in order to design a potential vaccine for the monkeypox virus.

The final predicted vaccine is a multiepitope vaccine (MEV) construct that comprises all identified epitopes fused altogether to elicit an optimal immune response. Afterwards, the structural, immunogenic and physicochemical parameters were evaluated for the designed MPXV-MEV. Additionally, molecular docking was performed to investigate the affinity of the vaccine construct towards the human toll-like receptor 5 (TLR5). Later, the molecular dynamics (MD) simulations confirmed the stability of the MPXV-MEV construct with the TLR5 receptor and the associated interactions. Further, immune simulations were carried out to ascertain the immune response profile of the vaccine candidate.
Table 1. Glycoproteins and membrane proteins of monkeypox virus strain W-Nigeria and their antigenic and allergic potential.

| GenBank Protein ID | Protein Name                                                                                     | Length (Amino Acids) | Vaxijen Score | Allergen (AllergenFP) |
|--------------------|--------------------------------------------------------------------------------------------------|----------------------|---------------|------------------------|
| AIE40790.1         | putative membrane-associated glycoprotein                                                        | 1880                 | 0.5262 (Antigenic) | Allergen               |
| AIE40786.1         | IFN-alpha/beta-receptor-like secreted glycoprotein                                               | 352                  | 0.5453 (Antigenic) | Non-allergen           |
| AIE40780.1         | bifunctional 21 kDa precursor protein of 18 kDa membrane protein                                 | 182                  | 0.4395 (Antigenic) | Allergen               |
| AIE40778.1         | EEV type-I membrane glycoprotein                                                                | 317                  | 0.5786 (Antigenic) | Non-allergen           |
| AIE40774.1         | bifunctional hemagglutinin/type-I membrane glycoprotein                                          | 313                  | 0.4638 (Antigenic) | Allergen               |
| AIE40766.1         | putative type-I membrane glycoprotein                                                           | 196                  | 0.5230 (Antigenic) | Non-allergen           |
| AIE40764.1         | bifunctional secreted glycoprotein                                                              | 221                  | 0.3864 (Non-antigenic) | Allergen               |
| AIE40763.1         | CD47-like putative membrane protein                                                             | 277                  | 0.4324 (Antigenic) | Non-allergen           |
| AIE40759.1         | EEV glycoprotein                                                                                | 168                  | 0.3728 (Non-antigenic) | Non-allergen               |
| AIE40758.1         | bifunctional EEV membrane phosphoglycoprotein                                                   | 181                  | 0.4998 (Antigenic) | Allergen               |
| AIE40739.1         | IV and IMV membrane protein                                                                     | 53                   | 0.7480 (Antigenic) | Non-allergen           |
| AIE40738.1         | phosphorylated IMV membrane protein                                                             | 90                   | 0.4759 (Antigenic) | Non-allergen           |
| AIE40737.1         | IMV membrane protein                                                                            | 70                   | 0.5019 (Antigenic) | Non-allergen           |
| AIE40733.1         | IMV membrane protein                                                                            | 100                  | 0.3923 (Non-antigenic) | Non-allergen               |
| AIE40718.1         | IMV membrane protein                                                                            | 304                  | 0.5316 (Antigenic) | Non-allergen           |
| AIE40702.1         | late 16 kDa putative membrane protein                                                            | 133                  | 0.7559 (Antigenic) | Non-allergen           |
| AIE40669.1         | membrane protein                                                                                | 273                  | 0.4199 (Antigenic) | Non-allergen           |
| AIE40657.1         | palmytilated EEV membrane protein                                                               | 372                  | 0.4754 (Antigenic) | Allergen               |

2. Methodology
2.1. Retrieval and Analysis of Protein Sequence

The sequence of the MPXV strain W-Nigeria (Accession number: KJ642615.1) was obtained from the GenBank database. A total of 176 proteins in the proteome of MPXV strain W-Nigeria were characterized, where we filtered only glycoproteins and membrane proteins for further analysis, see Table 1. Further, the antigenicity and allergic potential of all the chosen proteins were determined. Vaxijen v2.0 webserver was used to determine the antigenicity [26]. Vaxijen v2.0 predicts the antigenic peptides with 70–89% accuracy and employs the alignment-free approach, which is based on the auto cross covariance.
(ACC) transformation of protein sequences into uniform vectors of principal amino acid properties. In the Vaxijen v2.0 webserver, the target organism selected was the virus and the protein sequences in plain format were used as input. AllergenFP v1.0 webserver was used to predict the allergic potential, since this server was found to be the most accurate in identifying both allergens and non-allergens in comparison with different tools such as AlgPred, AllerTOP, AllerHunter, and APPEL [27]. In the AllergenFP server, amino acid sequences were provided as plain text (single letter code).

2.2. Prediction of T-Cell and B-Cell Epitopes and to Determine Their Antigenicity, Ctoxicity, Allergenicity and Interferon-\(\gamma\) Activation Potential

To predict T-helper cell epitopes that might bind to MHC class II molecules, the NETMHC 2.3 website was used, whereas for the identification of T-cytotoxic cell epitopes that might bind to MHC class I molecules and elicit a cellular immune response, we used the NETMHC 4.0 website [28]. The NETMHC 2.3 webserver was preferred over other tools such as PickPocket, PRPPRED, MULTIPRED, ADT, and KISS since this webserver was found to be better in the earlier investigations where all these different tools for predicting peptides that bind to MHC were compared [29,30]. The protein sequences were pasted in FASTA format in both NETMHC 2.3 and NETMHC 4.0 webservers and inputs and a peptide length of 9 were selected. To predict CD4\(^+\) T cell epitopes, the HLA alleles selected were DRB1_0101, DRB1_0301, DRB1_0401, DRB1_0701, DRB1_0801, DRB1_0901, DRB1_1001, DRB1_1101, DRB1_1201, DRB1_1301, DRBI_1501, and DRB1_1602. Further, to predict CD8\(^+\) T cells, the HLA alleles selected were HLA-A0101, HLA A0201, HLA-A0301, HLA-A2402, HLA-A260, HLA-B0702, HLA-B0801, HLA-B2705, HLA-B3901, HLA-B4001, and HLA-B5801. Default parameters of the NETMHC 2.3 and NETMHC 4.0 webservers were used for the threshold for both the strong and weak binders. The IEDB B cell epitope prediction website’s Bepipred linear epitope prediction 2.0 approach was used to predict the multiple linear B cell epitopes [31]. The Vaxijen v2.0 webserver was used to determine the antigenicity of the predicted B-cell and T-cell epitopes [26]. The webservers AllergenFP, ToxinPred and IFNepitope were used to determine the antigenic, toxic, allergic and interferon-\(\gamma\) activation potential of the epitopes [27,32,33].

2.3. Analysing Epitope Conservancy

The epitopes conservation was predicted in membrane proteins and glycoproteins of the three monkeypox virus strains, namely MPXV-WRAIR7-61, Sierra Leone, and COP-58, by employing the IEDB Epitope Conservancy Tool [34]. The sequences of epitopes and the proteins from which the epitopes were identified for each strain were pasted as input in FASTA format. The epitopes that were conserved were selected among different monkeypox virus strains in order to overcome the limitations due to antigenic shift or drift. The epitopes exhibiting 100% identity in sequences among the selected monkeypox strains were selected since they possessed less probability of any mutation [34].

2.4. Designing a Vaccine Construct and to Determine Its Physiochemical Properties

Both the B cell and T cell epitopes which fulfilled the selection criterion of properties, such as antigenic, non-toxic, non-allergic and interferon-\(\gamma\) activation, were linked together using the GSS linker. Two adjuvants—flagellin protein (Salmonella typhimurium) and RS09—were also linked to form the multiepitope vaccine construct using the GGS linker [35,36]. In order to improve the stability of the MEV construct, Pan HLA DR-binding epitope was also added [37]. The ProtParam online tool was used to determine the physiochemical properties such as hydrophilicity, isoelectric point, number of amino acids, number of negatively or positively charged residues, solubility, aliphatic index, extinction co-efficient, and half-life [38]. Further, the webservers Vaxijen 2.0 and AllergenFP were used to determine the antigenicity and allergic potential of the vaccine construct.
2.5. Prediction of Immune Response Profile of MEV

The C-IMMSIM webserver (https://kraken.iac.rm.cnr.it/C-IMMSIM/, accessed on 10 August 2022) is a position-specific scoring matrices-based machine learning approach and is used to investigate the immune response profile of a vaccine construct. This online webserver was used to predict the immunogenicity and immune behavior towards the candidate MPXV-MEV in the present study [39]. An interval of four weeks as the minimum duration between the first two doses of the vaccine injection has been advised; however, the interval can be extended to eight weeks or 3–6 months in some cases [40,41]. Thus, the immune behavior of MPXV-MEV vaccine was analyzed using three injections at an interval of four weeks [42,43]. Default parameters were kept except for the time. The time steps used were kept equivalent to four and eight weeks.

2.6. Prediction of Binding Affinity of MPXV-MEV with TLR5 Using Molecular Modeling and Docking

The Alphafoldv2.0 program was employed to predict the 3-D structures of both the MPXV-MEV construct and immunogenic TLR5 [44,45]. Alphafoldv2.0, ProCheck and ProSA web server were then used to validate the tertiary structures of MPXV-MEV and TLR5 [46]. The pLDDT scores were available with Alphafoldv2.0 and the Ramachandran plots and Z-scores were generated using the ProCheck and ProSA web servers [46].

The HADDOCK server [47] was used for docking MPXV-MEV to TLR5 using the default parameters [47]. LQRVRELAVQ and EILDISRNQL sequences were predicted as the potential binding regions in flagellin and human TLR5 [45]. Thus, during the docking experiments, these sequences were defined as the part of ‘Active Residues’ while running the HADDOCK program.

2.7. Molecular Dynamic Simulations of MPXV-MEV Complexed with TLR5

Afterwards, the GROMACS 2019 simulation program was used to perform the molecular dynamic (MD) simulations [48]. The complex of TLR5 and MPXV-MEV was put into a cubic box and solvated with TIP3P water molecules to create a solvent layer of 10 Å thick. The parameters of the proteins were then modeled with Amber ff99SB-ILDN [49]. Then, an appropriate number of K+ ions were added to neutralize the charge. Further, the Joung–Cheatham ion model was used to add extra K+Cl− ions to create the bulk ionic strength, i.e., 0.15 M [50]. The simulation box had 228,291 water molecules, 615 K+ ions, and 612 Cl− ions. The system had a total number of atoms of 701,665. The minimization of the system was carried out with 50,000 steps using the steepest descent method with 1000 kJ/mol nm² position restraint on heavy atoms of the protein. Further, minimization was performed with no restraint on the protein. Later, equilibration of each system was performed in the phased manner. As the first step, a 100 ps NVT simulation was performed with restraint on protein heavy atoms. Secondly, a 100 ps NPT simulation with restraint on protein heavy atoms was carried out. Production simulations were performed while using the NPT ensemble for 100 ns. A temperature of 300 K was maintained with velocity rescaling with a 0.1 ps coupling time. Parrinello–Rahman barostat was used to maintain the pressure of 1 atm for NPT simulations with a coupling time of 2 ps [51]. Then, the leapfrog algorithm was used to integrate the equations of motion with a time step of 2.0 fs. The particle mesh Ewald (PME) summation was used to evaluate the total electrostatic interactions [52]. Coulomb and Van der Waals cut-offs of 1.0 nm were performed. In order to mimic the bulk behavior, the periodic boundary conditions in all directions were employed. The LINCS algorithm constrained the bond lengths with hydrogen [53]. At an interval of every 10 ps, the coordinates were kept collecting in the trajectory files. GROMACS tools were used for the trajectory processing and for most of the analysis. Three independent simulations, starting from different initial velocities and each for 100 ns, were performed. PYMOL and VMD softwares were used to create the molecular graphics images [54,55]. In-house Python scripts were used to plot the graphs. Indeed, our team has successfully
used a similar modeling and MD simulation to investigate the structural stability of protein and nucleic acid systems [56–60].

3. Results

3.1. Protein Sequence Retrieval and Analysis

Out of 176 proteins, 18 proteins were identified. These proteins are classified as glycoproteins and membrane proteins in the proteome of the monkeypox virus strain W-Nigeria. Table 1 lists these proteins along with their predicted antigenic and allergic potential. Filtering those proteins possessing both antigenic and non-allergic potential resulted in the identification of 10 glycoproteins or membrane proteins, see Table 1.

3.2. Prediction of T Cell and B Cell Epitopes and Analysis of Their Antigenic, Allergic, Toxic and Interferon-γ Activation Potential

Strong binder epitopes of the MHC alleles, i.e., MHC I and MHC II, were first identified. The number of epitopes that were determined as strong binders for MHC I was 384 (see Table S1). Similarly, the number of epitopes identified as strong binders for MHC II was 256 (see Table S2). Further, 15 B cell epitopes were predicted (see Table S3). Epitopes with a Vaxijen antigen score ≥ to 1.0 along with other filtering parameters, such as antigenic, non-allergic, non-toxic properties and interferon-γ potential, were finally selected for the candidate monkeypox MEV design. Altogether, seven epitopes (two CD4+ T cell epitopes, four CD8+ T cell epitopes and one linear B cell epitope) fulfilled the selection criterion and were chosen for designing the final MPXV-MEV (Table 2). All the selected seven epitopes had 100% sequence identity in the MPXV-WRAIR7-61, Sierra Leone, and COP-58 strains of monkeypox virus. Further, the epitopes population coverage analysis was performed using the IEDB population coverage analysis tool, see Supplementary Information for more information. The MHC-II (CD4+ Tcell) epitopes, which are RIYFVSLSL and FSIGGVIHL and MHC-I (CD8+ Tcell) epitopes, which are IYFVSLSLL, LKHKYGCSL, AYTSISVVF and RYPIIDIKW, showed a world population coverage of 85.97% and 87.03% respectively.

Table 2. The epitopes identified for vaccine engineering along with the analysis of their toxic, allergic, antigenic, and interferon-γ activation potential.

| Epitope     | Peptide or Protein | Vaxijen | Antigenicity | Allergenicity | Toxicity | Interferon Activation |
|-------------|--------------------|---------|--------------|---------------|----------|-----------------------|
| CD4+ T cell | RIYFVSLSL/AIE40786.1 | 1.6615  | Yes          | No            | No       | Yes                   |
| CD4+ T cell | FSIGGVIHL/AIE40778.1 | 1.2283  | Yes          | No            | No       | Yes                   |
| CD8+ T cell | IYFVSLSLL/AIE40786.1 | 1.4551  | Yes          | No            | No       | Yes                   |
| CD8+ T cell | LKHKYGCSL/AIE40766.1 | 1.2793  | Yes          | No            | No       | Yes                   |
| CD8+ T cell | AYTSISVVF/AIE40763.1 | 1.1050  | Yes          | No            | No       | Yes                   |
| CD8+ T cell | RYPIIDIKW/AIE40702.1 | 1.5629  | Yes          | No            | No       | Yes                   |
| B cell      | PFSAKCPPIE/AIE40786.1 | 1.1314  | Yes          | No            | No       | Yes                   |

3.3. Engineering Vaccine and to Determine Its Physiochemical Properties

The epitopes identified were conjugated using adjuvants and Pan HLA DR-binding epitopes (PADRE) to develop the MEV construct. The final predicted vaccine construct has 390 residues (Figure 1). The MPXV-MEV construct was predicted as stable, antigenic and non-allergic in nature. The physiochemical properties of the MEV construct, other than the aforementioned, are provided in the Supplementary Information, see Table S4.
Figure 1. Scheme of the predicted monkeypox multi-epitope vaccine (MPXV-MEV) construct.

3.4. Performing Modeling and Docking of TLR5 MPXV-MEV Construct

The 3D structures of both MPXV-MEV and the immunogenic TLR5 receptor were predicted using the AlphaFoldv2.0 program [44,45]. Since no experimental structure is available for TLR5, the structure of TLR5 (Uniprot id: D1CS82) was obtained from AlphaFold prediction, which resulted in high pLDDT values with confidence scores >90% for most of the residues, indicating high confidence for prediction, see Figure S1. We particularly targeted the ectodomain residues (amino acids from 1–639) of the topological domain, which are primarily involved in the interaction with the extracellular signal; however, the transmembrane and TIR domain residues (amino acids from 640–836) are precluded from consideration in our analyses. Next, the structural prediction of the MPXV-MEV construct using AlphaFold resulted in high pLDDT values with confidence scores > 90% for the N- and C-terminal regions of the vaccine construct. However, a low confidence score with pLDDT values of <50% were predicted for the regions where adjuvants/linkers and epitope sequences were present (amino acids from 142–303), see Figure S1. Further, the quality of predicted structures was confirmed with a Ramachandran plot and the Z-scores of the modelled TLR5 and MPXV-MEV construct from the ProSA webserver [46]. For the MPXV-MEV construct, 96.7% of residues were observed in the favored regions; 2.9% residues were identified in the allowed and generously allowed regions; however, 0.4% residues were found under disallowed regions, see Figure 2A. Of the amino acids, 98.9% were observed in the core acceptable region; however, the other 1.1% were observed under the allowed region and generously allowed region for the TLR5 receptor, see Figure 2A. In order to investigate the interaction between the MEV construct and TLR5 involved in the immune response, molecular docking of MPXV-MEV was performed with TLR5 using the HADDOCK 2.4 web server and the default parameters [44]. Since flagellin, a bacterial adjuvant, specifically interacts with TLR5 which might invoke the innate immune response,
an information-driven docking was performed, based on the information about specific interacting residues, to drive the docking simulations [36]. An analogous approach using a complementary hydrophathy between the flagellin and TLR5 has previously been used for predicting the potential binding regions and the structure of the overall complex [61]. In a recent study, it has been shown that the potential binding regions identified for flagellin and human TLR5 were LQRVRELAVQ and EILDISRNQL [45]. Thus, during the docking experiments, these sequences were defined as the part of ‘Active Residues’ while running the HADDOCK program. The top ranked cluster containing the lowest HADDOCK score was selected as a final structure of the MPXV-MEV and TLR5 complex. The molecular docking between the MPXV-MEV construct and the TLR5 receptor is shown in Figure 2B. Further, we specifically computed the “distance range maps” for the docked complex using the COCOMAPS tool, see Figure 2B. In order to define a contact, a cut-off distance of 5 Å between two atoms was used. Forty-six contacts existed between hydrophilic residues, 50 were observed between hydrophilic and hydrophobic residues, and 11 existed in between two hydrophobic residues.

Figure 2. (A) Modeled 3D structures of (A) TLR5 and MPXY-MEV construct. Ramachandran plots and Z-scores calculated by Pro-SA webserver below the predicted structures. (B) Docked structure of MPXV-MEV and TLR5 as blue and red cartoons. The hotspot residues used for information-driven docking illustrated as spheres in green and magenta colors for the MEV construct and TLR5 receptor, respectively. Distance contact maps are also plotted, indicating the residues in contact between MPXV-MEV and the TLR5 receptor along with two representative molecular interactions between amino acid residues of TLR5 and the MPXV-MEV construct.
3.5. Structural Stability of the MPXV-MEV Complexed with TLR5

MD simulations were performed to study the structural stability of the docked complex of MPXV-MEV and TLR5 [60]. GROMACS software was used to perform three different MD simulations, each 100 ns long, starting with different initial velocities [26], which produced very similar results, see Figure S2. Herein, we discuss the results for one of the simulations. To investigate the stability the MPXV-MEV complexed with TLR5, the root mean square deviation (RMSD) of the Cα atoms from their initial position was monitored as a function of simulation time. It is evident from Figure 3A that the structure of the complex stabilizes after 30ns simulation time. The RMSD calculated for the docked TLR5 and MPXV-MEV complex after initial 30 ns of simulations is $1.08 \pm 0.1$ nm. Further, RMSD values were plotted separately for TLR5 and MPXV-MEV as well, see Figure 3A. Indeed, TLR5 alone was considerably stable after 30 ns (see Figure 3A and Figure S2A), with an average RMSD of $0.52 \pm 0.04$ nm. The predicted MPXV-MEV had flexibility with an RMSD value of $1.17 \pm 0.09$ nm. However, the RMSD values observed for trial-2 of MPXV-MEV are still not stable during the 100 ns simulation run, which may indicate a longer simulation run is required for attaining stability. Root mean square fluctuation (RMSF) was plotted separately for the TLR5 and the MPXV-MEV construct in order understand the structure’s flexibility on a residue basis. The elevated RMS fluctuations were observed for the highly flexible regions, see Figure 3B. It is evident that the Cα atoms of the entire TLR5 structure have a limited flexibility with an average RMSF of $0.22 \pm 0.12$ nm. On the other hand, a high fluctuation was found, particularly for the regions associated with N- and C-terminal of flagellin in the MPXV-MEV construct with an RMSF of $0.41 \pm 0.20$ nm and $0.38 \pm 0.19$ nm, respectively. Additionally, the number of intermolecular hydrogen bonds in the complex of TLR5 and MPXV-MEV remained constant after 30ns simulation time (Figure 3C). The buried surface area at the interface of the MPXV-MEV and TLR5 complex was stable throughout the simulation time, which clearly implies the stability of interface interaction between MPXV-MEV and TLR5 (Figure 3D). Further, we calculated the interaction energies between TLR5 and MPXV-MEV, i.e., the Lennard–Jones (E(LJ)) potential component, which stands for the Van der Waals interactions and the coulombic component (E(Coul)), representing the electrostatics interaction. From Figure S3, it is evident that both the electrostatic and LJ components contribute almost equally to the stabilization of the overall TLR5 and MPXV-MEV complex, with electrostatics energy of $-714.65 \pm 90.9$ kcal/mol and an E(LJ) contribution of $-665.89 \pm 61.5$ kcal/mol.

The superimposition of complex structures extracted every 20 ns during the simulation time resulted in good overlap, with RMSD values below 1 nm (Figure 3E); a limited flexibility was only observed in the terminal regions of the MPXV-MEV construct. An interface analysis was performed using the COCOMAPS tool for the same selected snapshots [62,63] (see, Figure 3F). Distance range maps were specifically plotted. The dots at the crossover of two residues belonging to the MPXV-MEV construct and to TLR5 are represented as red, yellow, green and blue if any pair of their atoms is closer than 7, 10, 13 and 16 Å. It is evident from Figure 3F that the interface remains stable for the selected snapshots in terms of inter-residue contacts, despite the observed peripheral flexibility of the MPXV-MEV construct.

Further, the MDcons program was used to assess the stability of the complex between MPXV-MEV and TLR5, and the conservation of inter-residue contacts (ICs) at the interface along the simulation time was plotted [64–69]. The similarity between different snapshots focused on the region of interest, which is the biomolecular interface, could be efficiently measured by the conservation of ICs under dynamic conditions between macromolecules giving a stable complex. Figure 4A,B illustrate a consensus map of 1000 MD snapshots and distances along the simulation time for two selected conserved ICs, respectively. The overall conservation of the ICs at the MPXV-MEV and TLR5 interface during the MD simulations is illustrated in the MD consensus map which clearly indicates that many contacts between the MPXV-MEV construct and TLR5 remained stable throughout the simulation time (Figure 4A). MDcons analysis produced C$_{50}$ and C$_{70}$ values of 0.87 and
0.51, implying that 87% and 51% of ICs were kept conserved for at least 50% and 70% of the frames. Hence, quite a high conservation of the complex interface during the simulation time was observed. The ICs remained stable over the simulation time and two such examples are shown in Figure 4B. Notably, the H-bond existing between Tyr513 from TLR5 and Arg93 from the N-terminal of flagellin on the MPXV-MEV construct remained stable throughout the simulation time with an average Tyr513(OH)-Arg230(CZ) distance of 0.41 ± 0.05 nm. The hydrogen bonding interaction between Ser132 of TLR5 and Arg348 from the C-terminal of flagellin on the MPXV-MEV construct was also observed to remain stable with an average Ser132(OG)-Arg348(CZ) distance of 0.44 ± 0.05 nm.

Figure 3. (A) Backbone RMSD plots of the docked complex and the individual chains of TLR5 and MPXV-MEV construct; (B) RMSF plots; (C) Hydrogen bonds analysis between TLR5 and MPXV-MEV during MD simulations; (D) Buried area of TLR5 and MPXV-MEV construct; (E) Superimposition of snapshots at every 20 ns of the TLR5 and MPXV-MEV constructs with their respective RMSD; (F) Contact maps showing inter-molecular contacts where the dots at the crossover of two amino acids have been colored in red, yellow, green and blue if any pair of atoms between two amino acids is closer than 7, 10, 13 and 16 Å.
time (Figure 4A). MDcons analysis produced C50 and C70 values of 0.87 and 0.51, implying that 87% and 51% of ICs were kept conserved for at least 50% and 70% of the frames. Hence, quite a high conservation of the complex interface during the simulation time was observed. The ICs remained stable over the simulation time and two such examples are shown in Figure 4B. Notably, the H-bond existing between Tyr513 from TLR5 and Arg93 from the N-terminal of flagellin on the MPXV-MEV construct remained stable throughout the simulation time with an average Tyr513(OH)-Arg230(CZ) distance of 0.41 ± 0.05 nm. The hydrogen bonding interaction between Ser132 of TLR5 and Arg348 from the C-terminal of flagellin on the MPXV-MEV construct was also observed to remain stable with an average Ser132(OG)-Arg348(CZ) distance of 0.44 ± 0.05 nm.

3.6. Immune Simulation

The immune simulation demonstrated that the first exposure to the candidate monkeypox MEV did not elevate the antibody titer significantly. However, the next two injections considerably increased the antibody titer (IgM + IgG, IgM, IgG1 + IgG2, and IgG1) relative to the first dose of MEV (Figure 5A). The third dose also elevated IgG2 titer. The C-IMMSIM also determined that candidate monkeypox MEV has the potential to grow the total B-lymphocytes population after each injection (Figure 5B). An increase in B isotype IgG1 and B isotype IgM were also predicted (Figure 1B). Further, the expression of B memory cells was increased after each vaccine dose, implying a robust secondary immune response activation (Figure 5B). The total population of CD4⁺ T1 was also increased following every vaccination. Moreover, the population of memory T cells was increased following each vaccination (Figure 5C). However, the total CD4⁺ T cell population remained the same after the second and third doses of MEV (Figure 5C). Furthermore, there was an increase in the population of active CD4⁺ T cells after the vaccination (Figure 5D). The resting and duplic-
cating CD4+ T cells were increased after the first two injections; however, after the third injection, their population slightly decreased (Figure 5D). Thus, a rise in memory B cells and resting T cells after vaccination implies the activation of the adaptive immune response on which the vaccination is based. The candidate MPXV-MEV vaccination also stimulated the production of interleukin-10, interleukin-12, interferon-γ and TGF-β (Figure 5E). Initially, an increase in these cytokines and interleukins was observed after the first two vaccinations; however, their concentration was decreased after the third dose compared to the first two shots (Figure 5E). Overall, the immune simulations predicted that candidate MPXV-MEV vaccination could activate the immune response.

Figure 5. The immune response predicted using C-IMMSIM (A) antigen count and antibody titer with specific subclass; (B) B cell; (C) CD4+ T cell; (D) CD4+ T cell population per state; (E) cytokines and interleukins.

4. Discussion

Monkeypox is an orthopoxvirus, which is responsible for infectious diseases such as cowpox, smallpox, camelpox, and horsepox [70]. The monkeypox contains double-stranded DNA which is approximately 197 kb and contains 190 non-overlapping open reading frames [71]. Monkeypox virus has been detected in various animals such as Gambian rats, Asian monkeys, rhesus macaques, prairie dogs and rope squirrels [72,73]. Moreover, Gambian-pouched rats have also been speculated to be the reservoir host species of MPXV [74]. Monkeypox is reported to infect a broad range of hosts; intriguingly, the natural host of the virus has still not been identified [73]. Either of the two modes of transmission, i.e., animal-to-human or human-to-human, can infect humans [73]. The symptoms include skin rashes, fever, fatigue, lesions, and lymphadenopathy [75]. Further complications include dehydration, vomiting, conjunctivitis, encephalitis, pharyngitis, tonsillitis, and diarrhea [75].
The currently available vaccines that have provided immunization against monkeypox include FDA approved ACAM2000 or NYCBH and LC16m8 which are under clinical trials. These vaccines are live, attenuated vaccinia viruses which face challenges of safety and efficacy in chronic infections [76,77]. Furthermore, there is a risk of virulence reversion due to complementing mutations in vaccine recipients or production hosts during vaccine viruses’ replication [76,77]. Moreover, in light of the recent multi-country monkeypox outbreak and the lack of any specific treatment for the same, it has become imperative to look for new ways to treat and protect the human population from monkeypox. Hence, an immunoinformatics approach seems to be exciting for designing a potential vaccine candidate to explore an alternative to the live attenuated virus. Furthermore, the epitope-based vaccines could help to overcome challenges such as genetic variations, antigenic shift and antigenic drift. Previously, various epitope-based vaccine candidates against pathogens such as bacteria, viruses, fungi, parasites and cancers have been designed using an in silico immunoinformatics approach [23,42,78–88]. Recently, an MEV showing a T-cell response for Q fever in cynomolgus macaques has been reported [79]. Quite recently, immunoinformatics-based designs of vaccines have also been proposed, targeting various proteins for MPXV [89–92].

The epitopes ISPDGCYSL and LTFDYVVTF, which were derived from the F8L protein of the monkeypox virus, have been reported to activate the CD8+ T cell population and the release of interferon-γ in rhesus macaques [93]. Interestingly, an epitope-based vaccine, VennVax, exhibits 100% protective efficacy against vaccinia virus by activating T cell response in the humanized mouse model. Interestingly, VennVax has recently been found to be effective as an MPXV cure as well [94,95].

In the present study, the membrane proteins and glycoproteins were targeted for predicting antigenic epitopes to design a potential MEV candidate against monkeypox. These proteins are major constituents of pathogenic viruses and play a significant role in immunity and pathogenesis [96], and are involved in the attachment to the host cellular receptors and virus–host membrane fusion [96]. In this study, seven epitopes (two cell epitopes, four cell epitopes and one linear B cell epitope) possessed antigenicity, non-allergenicity, and non-toxicity. Furthermore, these epitopes were also predicted to activate interferon-γ production. Interferon-γ modulates both the innate and adaptive immunity while contributing to the antiviral defense system [97]. Then, the selected epitopes were linked with adjuvants and the PADRE sequence to design a novel monkeypox MEV candidate. Furthermore, the candidate monkeypox MEV was predicted to be antigenic and non-allergic. Further, the docking and MD simulations of MPXV-MEV complexed with the TLR5 receptor resulted in a stable interaction pattern especially at the biological interface of this complex. The computational analyses emphasize that the novel MPXV-MEV construct identified is a potent immunogen which exhibits both non-allergenicity and non-toxicity. Interestingly, the vaccine construct is dissimilar to human proteins (taxid: 9606; Homo sapiens) in a protein–protein BLAST analysis, indicating that it could be safely used for humans.

5. Conclusions

The immunogenic and non-allergic glycoproteins and membrane proteins for MPXV have been targeted in order to predict epitopes for T-cells and B-cells that could be used to design a candidate MEV against MPXV. The predicted MPXV-MEV is antigenic and non-allergic in nature and interacts strongly with human TLR5. In silico immune simulation of the MEV construct predicted that the vaccine candidate could elicit an immune response in humans.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v14112374/s1, Figure S1: Modeling of MPXV-MEV construct and TLR5 receptor using AlphaFold; Figure S2: Molecular dynamics simulations results obtained from three independent simulations for Root Mean Square Deviation (RMSD) for (A) TLR5 and (B) MAXV-MEV. (C) Total number of hydrogen bonds between TLR5 and MPXV-MEV; Figure S3: Interaction energy between TLR5 and MAXV-MEV obtained from three independent simulations; Table S1:
Prediction of helper T cell epitopes and their antigenicity, allergenicity, toxicity and interferon-γ inducing ability; Table S2: Prediction of cytotoxic T cell epitopes and their antigenicity, allergenicity, toxicity and interferon-γ inducing ability; Table S3: Prediction of B cell epitopes and their antigenicity, allergenicity, toxicity and interferon-γ inducing ability; Table S4: Physiochemical Properties of the MPXV-MEV construct.

Author Contributions: Conceptualization, M.C., V.K. and A.R.S.; Methodology, N.A., A.R.S., C.S., A.R.S., K.C. and M.C.; Software, A.R.S., R.K.G., R.O. and A.K.W.; Validation, M.C., A.R.S. and R.O.; Formal Analysis, N.A., A.R.S., C.S., K.C., V.K., R.O. and M.C.; Investigation, M.C. and A.R.S.; Resources, L.C. and K.C.; Data Curation, N.A., A.R.S., C.S., K.C., V.K., R.O. and M.C.; Writing—Original Draft Preparation, N.A., A.R.S. and M.C.; Writing—Review & Editing, M.C., R.K.G., A.R.S. and R.O.; Visualization, M.C. and A.R.S.; Supervision, M.C. and A.R.S.; Project Administration, M.C. and A.R.S.; Funding Acquisition, L.C. and K.C. All authors have read and agreed to the published version of the manuscript.

Funding: The research carried out was supported by King Abdullah University of Science and Technology: BAS funding to L.C. R.O. would like to thank MIUR-FFABR “Fondo per il Finanziamento Attività Base di Ricerca” for funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article and the Supplementary Material.

Acknowledgments: L.C. and M.C. acknowledge the KAUST Core Labs and Supercomputing Laboratory for providing computational resources on the HPC platform Shaheen II. Team members from STEMskills Research and Education Lab Private Limited are acknowledged for the critical reading of manuscript and computational support. Further, this work is also financial supported by the Office of the Ministry of Higher Education, Science, Research and Innovation; and the Thailand Science Research and Innovation through the Kasetsart University Reinventing University Program 2022.

Conflicts of Interest: The authors declare the following competing financial interest(s): Authors R.K.G. and A.R.S. were employed by the company STEMskills Research and Education Lab Private Limited, Faridabad, Haryana, India. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References
1. Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; et al. Monkeypox Virus Infection in Humans across 16 Countries—April–June 2022. N. Engl. J. Med. 2022, 8, 679–691. [CrossRef]
2. Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl. Trop. Dis. 2022, 16, e0010141. [CrossRef]
3. Ladnyj, I.D.; Ziegler, P.; Kima, E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull. World Health Organ. 1972, 46, 593–597.
4. Saxena, S.K.; Ansari, S.; Maurya, V.K.; Kumar, S.; Jain, A.; Paweska, J.T.; Tripathi, A.K.; Abdel-Moneim, A.S. Re-emerging human monkeypox: A major public-health debacle. J. Med. Virol. 2022. [CrossRef]
5. Parker, S.; Buller, R.M. A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. Futur. Virol. 2013, 8, 129–157. [CrossRef] [PubMed]
6. Besombes, C.; Gonofio, E.; Konamna, X.; Selekon, B.; Grant, R.; Gessain, A.; Berthet, N.; Manuguerra, J.C.; Fontanet, A.; Nakoune, E. Intrafamily Transmission of Monkeypox Virus, Central African Republic, 2018. Emerg. Infect. Dis. 2019, 25, 1602–1604. [CrossRef] [PubMed]
7. Mauldin, M.R.; McCollum, A.M.; Nakazawa, Y.J.; Mandra, A.; Whitehouse, E.R.; Davidson, W.; Zhao, H.; Gao, J.; Li, Y.; Doty, J.; et al. Exportation of Monkeypox Virus From the African Continent. J. Infect. Dis. 2020, 225, 1367–1376. [CrossRef] [PubMed]
8. Petersen, E.; Kantele, A.; Koopmans, M.; Asogun, D.; Yinka-Ogunleye, A.; Ihekweazu, C.; Zumla, A. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect. Dis. Clin. N. Am. 2019, 33, 1027–1043. [CrossRef] [PubMed]
9. Kumar, S.; Subramaniam, G.; Karuppanan, K. Human monkeypox outbreak in 2022. J. Med. Virol. 2022. [CrossRef] [PubMed]
10. Petersen, B.W.; Kabamba, J.; McCollum, A.M.; Lushima, R.S.; Wemakoy, E.O.; Tamflum, J.-J.M.; Nguete, B.; Hughes, C.M.; Monroe, B.P.; Reynolds, M.G. Vaccinating against monkeypox in the Democratic Republic of the Congo. Antivir. Res. 2018, 162, 171–177. [CrossRef] [PubMed]
11. Petersen, B.W.; Harms, T.J.; Reynolds, M.G.; Harrison, L.H. Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses—Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. *Morb. Mortal. Wkly. Rep.* 2016, 65, 257–262. [CrossRef] [PubMed]

12. Sbrana, E.; Jordan, R.; Hrubý, D.E.; Mateo, R.I.; Xiao, S.Y.; Siirin, M.; Newman, P.C.; Da Rosa, A.P.A.T.; Tesh, R.B. Efficacy of the Antivirus Compound St-246 for Treatment of Severe Orthopoxvirus Infection. *Am. J. Trop. Med. Hyg.* 2007, 76, 768–773. [CrossRef] [PubMed]

13. Jordan, R.; Goff, A.; Frimm, A.; Corrado, M.L.; Hensley, L.; Byrd, C.M.; Mucker, E.; Shamblin, J.; Bolken, T.C.; Wlazlowski, C.; et al. ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. *Antimicrob. Agents Chemother.* 2009, 53, 1817–1822. [CrossRef] [PubMed]

14. O’Shea, J.; Filardo, T.D.; Morris, S.B.; Weiser, J.; Petersen, B.; Brooks, J.T. Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection—United States, August 2022. *Morb. Mortal. Wkly. Rep.* 2022, 71, 1023–1028. [CrossRef]

15. Rizk, J.G.; Lippi, G.; Henry, B.M.; Forthal, D.N.; Rizk, Y. Prevention and Treatment of Monkeypox. *Drugs* 2022, 82, 957–963. [CrossRef]

16. Johnston, S.C.; Lin, K.L.; Connor, J.H.; Ruthel, G.; Goff, A.; E Hensley, L. In vitro inhibition of monkeypox virus production and spread by Interferon-β. *Virol. J.* 2012, 9, 5. [CrossRef]

17. Iizuka, I.; Ami, Y.; Suzaki, Y.; Nagata, N.; Fukushi, S.; Ogata, M.; Morikawa, S.; Hasegawa, H.; Mizuguchi, M.; Kurane, I.; et al. A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox. *Jpn. J. Infect. Dis.* 2017, 70, 408–415. [CrossRef]

18. Denzler, K.L.; Babas, T.; Rippeon, A.; Huynh, T.; Fukushima, N.; Rhodes, L.; Silvera, P.M.; Jacobs, B.L. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cyno-molgus macaques. *Vaccine* 2011, 29, 9684–9690. [CrossRef]

19. Bhardwaj, A.; Sharma, R.; Grover, A. Immunoinformatics guided designing of a multi-epitope vaccine against Dengue and Zika. *J. Biomol. Struct. Dyn.* 2021, 1–15. [CrossRef]

20. Dixit, N.K. Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach. *Int. J. Pept. Res. Ther.* 2021, 27, 2607–2624. [CrossRef]

21. Ali, M.; Pandey, R.K.; Khatoon, N.; Narula, A.; Mishra, A.; Prajapati, V.K. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. *Sci. Rep.* 2017, 7, 9232. [CrossRef] [PubMed]

22. Cuspoca, A.F.; Diaz, L.L.; Acosta, A.F.; Penaloza, M.K.; Mendez, Y.R.; Clavijo, D.C.; Reyes, J.Y. An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World’s Population. *Vaccines* 2021, 9, 581–585. [CrossRef] [PubMed]

23. Krishnan, S.; Joshi, A.; Akhtar, N.; Kaushik, V. Immunoinformatics designed T cell multi epitope dengue peptide vaccine derived from non structural proteome. *Microb. Pathog.* 2021, 150, 104728. [CrossRef]

24. Kaushik, V.; Krishnan, S.; Gupta, L.R.; Kalra, U.; Shaikh, A.R.; Cavallo, L.; Chawla, M. Immunoinformatics Aided Design and In-Vivo Validation of a Cross-Reactive Peptide Based Multi-Epitope Vaccine Targeting Multiple Serotypes of Dengue Virus. *Front. Immunol.* 2022, 13, 865180. [CrossRef]

25. Kaushik, V.; Jain, P.; Akhtar, N.; Joshi, A.; Gupta, L.R.; Grewal, R.K.; Oliva, R.; Shaikh, A.R.; Cavallo, L.; Chawla, M. Immunoinformatics-Aided Design and In Vivo Validation of a Peptide-Based Multiepitope Vaccine Targeting Canine Circovirus. *ACS Pharmacol. Transl. Sci.* 2022, 5, 679–691. [CrossRef]

26. Doytchinova, I.A.; Flower, D.R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. *J. Biomol. Struct. Dyn.* 2007, 4, 1–15. [CrossRef]

27. Dimitrov, I.; Naneva, L.; Doytchinova, I.; Bangov, I. AllergenFP: Allergenicity prediction by descriptor fingerprints. *Bioinformatics* 2013, 30, 846–851. [CrossRef]

28. Reynisson, B.; Alvarez, B.; Paul, S.; Peters, B.; Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC class I- and II-bound peptides. *Nucleic Acids Res.* 2020, 48, W449–W454. [CrossRef]

29. Zhang, L.M.; Udaka, K.; Mamitsuka, H.; Zhu, S.F. Toward more accurate pan-specific MHC-peptide binding prediction: A review of current methods and tools. *Brief. Bioinform.* 2012, 13, 350–364. [CrossRef]

30. Lin, H.H.; Zhang, G.L.; Tongchusak, S.; Reinherz, E.L.; Brusic, V. Evaluation of MHC-II peptide binding predic-tion servers: Applications for vaccine research. *BMC Biol.* 2008, 9, S22. [CrossRef]

31. Larsen, J.E.P.; Lund, O.; Nielsen, M. Improved method for predicting linear B-cell epitopes. *Immunome Res.* 2006, 2, 2. [CrossRef] [PubMed]

32. Dhanda, S.K.; Vir, P.; Raghava, G.P.S. Designing of interferon-gamma inducing MHC class-II binders. *Biol. Direct* 2013, 8, 30. [CrossRef] [PubMed]

33. Gupta, S.; Kapoor, P.; Chaudhary, K.; Gautam, A.; Kumar, R.; Raghava, G.P.S.; Open Source Drug Discovery Consortium. In Silico Approach for Predicting Toxicity of Peptides and Proteins. *PLoS ONE* 2013, 8, e73957. [CrossRef] [PubMed]

34. Bul, H.H.; Sidney, J.; Li, W.; Fusseder, N.; Sette, A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. *BMC Bioinform.* 2007, 8, 361. [CrossRef]
35. Gupta, S.K.; Bajwa, P.; Deb, R.; Chellappa, M.M.; Dey, S. Flagellin A Toll-Like Receptor 5 Agonist as an Adjuvant in Chicken Vaccines. *Clin. Vaccine Immunol.* **2014**, *21*, 261–270. [CrossRef]

36. Forstneric, V.; Ivicak-Kocjan, K.; Plaper, T.; Jeral, R.; Bencina, M. The role of the C-terminal D0 domain of flagellin in activation of Toll like receptor 5. *PLoS Pathog.* **2017**, *13*, e1006574. [CrossRef]

37. La Rosa, C.; Longmate, J.; Lacey, S.F.; Kaltcheva, T.; Sharan, R.; Marsano, D.; Kwon, P.; Drake, J.; Williams, B.; Denison, S.; et al. Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. *J. Infect. Dis.* **2012**, *205*, 1294–1304. [CrossRef]

38. Gasteiger, E.; Hoogland, C.; Gattiker, A.; Duvaud, S.; Wilkins, M.; Appel, R.; Bairoch, A. *The Proteomics Protocols Handbook*; Humana Press Inc.: Totowa, NJ, USA, 2005.

39. Rapin, N.; Lund, O.; Bernaschi, M.; Castiglione, F. Computational Immunology Meets Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune System. *PLoS ONE* **2010**, *5*, e9862. [CrossRef]

40. Castiglione, F.; Mantile, F.; De Berardinis, P.; Prisco, A. How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System. *Comput. Math. Methods Med.* **2012**, *2012*, 842329. [CrossRef]

41. Robinson, C.L.; Romero, J.R.; Kempe, A.; Pellegrini, C. Advisory Committee on Immunization Practices (ACIP) Child/Adolescent Immunization Work Group Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017. *MMWR. Morb. Mortal. Wkly. Rep.* **2017**, *66*, 134–135. [CrossRef]

42. Safavi, A.; Kefayat, A.; Abiri, A.; Mahdevar, E.; Behnia, A.H.; Ghahremani, F. In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. *Mol. Immunol.* **2019**, *112*, 93–102. [CrossRef]

43. Safavi, A.; Kefayat, A.; Mahdevar, E.; Abiri, A.; Ghahremani, F. Exploring the out of sight antigen of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing bioinformatics approaches. *Vaccine* **2020**, *38*, 7612–7628. [CrossRef] [PubMed]

44. David, A.; Islam, S.; Tankhilevich, E.; Sternberg, M.J.E. The AlphaFold Database of Protein Structures: A Biologist’s Guide. *J. Mol. Biol.* **2022**, *434*, 167336. [CrossRef] [PubMed]

45. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. *Nature 2021*, *596*, 583–589. [CrossRef] [PubMed]

46. Wiederstein, M.; Sippl, M.J. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res.* **2005**, *33*, W407–W410. [CrossRef] [PubMed]

47. van Zundert, G.C.P.; Rodrigues, J.; Trellet, M.; Schmitz, C.; Kastritis, P.L.; Karaca, E.; Melquinond, A.S.J.; van Dijk, M.; de Vries, S.J.; Bonvin, A. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Com-plexes. *J. Mol. Biol.* **2016**, *428*, 720–725.

48. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **2015**, *1–2*, 19–25. [CrossRef]

49. Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J.L.; Dror, R.O.; Shaw, D.E. Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins Struct. Funct. Bioinform.* **2010**, *78*, 1950–1958. [CrossRef]

50. Joung, I.S.; Cheatham, T.E. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. *J. Phys. Chem. B* **2008**, *112*, 9020–9041. [CrossRef]

51. Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl. Phys.* **1981**, *52*, 7182–7190. [CrossRef]

52. Darden, T.; York, D.; Pedersen, L. Particle Mesh Ewald—An N.log(N) Method for Ewald Sums in Large Systems. *J. Chem. Phys.* **1993**, *98*, 10089–10092. [CrossRef]

53. Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. LINCS: A linear constraint solver for molecular simulations. *J. Phys. Chem. B* **2001**, *105*, 7182–7190. [CrossRef]

54. Chawla, M.; Credendino, R.; Poater, A.; Oliva, R.; Cavallo, L. Structural Stability, Acidity, and Halide Selectivity of the Fluoride Riboswitch Recognition Site. *J. Am. Chem. Soc.* **2014**, *137*, 299–306. [CrossRef]

55. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. *J. Mol. Graph.* **1996**, *14*, 27–38. [CrossRef]

56. Oliveira, R.; Shaikh, A.R.; Petta, A.; Vangone, A.; Cavallaro, L. D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein: Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. *Molecules* **2021**, *26*, 2622. [PubMed]

57. Grewal, R.K.; Shaikh, A.R.; Gorle, S.; Kaur, M.; Videira, P.A.; Cavallaro, L.; Chawla, M. Structural Insights in Mammalian Sialyltransferases and Fucosyltransferases: We Have Come a Long Way, but It Is Still a Long Way Down. *Molecules* **2021**, *26*, 5203. [CrossRef]

58. Chawla, M.; Credendino, R.; Poater, A.; Oliva, R.; Cavallo, L. Structural Stability, Acidity, and Halide Selectivity of the Fluoride Riboswitch Recognition Site. *J. Am. Chem. Soc.* **2014**, *137*, 299–306. [CrossRef]

59. Chawla, M.; Gorle, S.; Shaikh, A.R.; Oliva, R.; Cavallo, L. Replacing thymine with a strongly pairing fifth Base: A combined quantum mechanics and molecular dynamics study. *Comput. Struct. Biotechnol. J.* **2021**, *19*, 1312–1324. [CrossRef]

60. Kalra, K.; Gorle, S.; Cavallo, L.; Oliva, R.; Chawla, M. Occurrence and stability of lone pair-pi and OH-pi interac-tions between water and nucleobases in functional RNAs. *Nucleic Acids. Res.* **2020**, *48*, 5825–5838. [CrossRef]

61. Jacchieri, S.G.; Torquato, R.; Bottani, R. R. Structural Study of Binding of Flagellin by Toll-Like Receptor 5. *J. Bacteriol.* **2003**, *185*, 4243–4247. [CrossRef] [PubMed]
62. Vangone, A.; Oliva, R.; Cavallo, L. CONS-COCOMAPS: A novel tool to measure and visualize the conservation of inter-residue contacts in multiple docking solutions. BMC Bioinform. 2012, 13, S19. [CrossRef] [PubMed]

63. Vangone, A.; Spinelli, R.; Scarno, V.; Cavallo, L.; Oliva, R. COCOMAPS: A web application to analyze and visualize contacts at the interface of biomolecular complexes. Bioinformatics 2011, 27, 2915–2916. [CrossRef] [PubMed]

64. Abdel-Azeim, S.; Cherrak, E.; Vangone, A.; Oliva, R.; Cavallo, L. MDcons: Intermolecular contact maps as a tool to analyze the interface of protein complexes from molecular dynamics trajectories. BMC Bioinform. 2014, 15, S1. [CrossRef] [PubMed]

65. Barradas-Bautista, D.; Cao, Z.; Cavallo, L.; Oliva, R. The CASP13-CAPRI targets as case studies to illustrate a novel scoring pipeline integrating CONSRANK with clustering and interface analyses. BMC Bioinform. 2020, 21, 262. [CrossRef]

66. Cherrak, E.; Donato, R.; Lensink, M.F.; Petta, A.; Serra, L.; Scarno, V.; Cavallo, L.; Oliva, R. Introducing a Clus-tering Step in a Consensus Approach for the Scoring of Protein-Protein Docking Models. PLoS ONE 2016, 11, e0166460. [CrossRef] [PubMed]

67. Oliva, R.; Cherrak, E.; Cavallo, L. Analysis and Ranking of Protein-Protein Docking Models Using Inter-Residue Contacts and Inter-Molecular Contact Maps. Molecules 2015, 20, 12045–12060. [CrossRef]

68. Vangone, A.; Oliva, L.; Oliva, R. Using a consensus approach based on the conservation of inter-residue con-tacts to rank CAPRI models. Proteins-Struct. Funct. Bioinform. 2013, 81, 2210–2220. [CrossRef] [PubMed]

69. Oliva, R.; Vangone, L.; Oliva, L. Ranking multiple docking solutions based on the conservation of inter-residue contacts. Proteins Struct. Funct. Bioinform. 2013, 81, 1571–1584. [CrossRef]

70. Silva, N.; de Oliveira, J.; Kroon, E.; Trindade, G.; Drumond, B. Here, There, and Everywhere: The Wide Host Range and Geographic Distribution of Zoonotic Orthopoxviruses. Viruses 2020, 13, 43. [CrossRef] [PubMed]

71. Kugelman, J.R.; Johnston, S.C.; Mulembakani, P.M.; Kisalu, N.; Lee, M.S.; Koroleva, G.; McCarthy, S.E.; Gestole, M.C.; Wolfe, N.D.; Fair, J.N.; et al. Geographical Variability of Monkeypox Virus among Humans, Democratic Republic of the Congo. Emerg. Infect. Dis. 2014, 20, 232–239. [CrossRef] [PubMed]

72. Guarner, J.; Johnson, B.J.; Paddock, C.D.; Shieh, W.-J.; Goldsmith, C.S.; Reynolds, M.; Damon, I.K.; Regnery, R.L.; Zaki, S.R. The Veterinary Monkeypox Virus Working Group Mon-keypox Transmission and Pathogenesis in Prairie Dogs. Emerg. Infect. Dis. 2004, 10, 426–431. [CrossRef] [PubMed]

73. Alakunle, E.; Moens, U.; Nchinda, G.; Okeke, M.I. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. Viruses 2020, 12, 1257. [CrossRef]

74. Hutson, C.L.; Nakazawa, Y.J.; Self, J.; Olson, V.A.; Regnery, R.L.; Braden, Z.; Weiss, S.; Malekani, J.; Jackson, E.; Tate, M.; et al. Laboratory Investigations of African Pouched Rats (Cricetomys gambianus) as a Potential Reservoir Host Species for Monkeypox Virus. PLoS Negl. Trop. Dis. 2015, 9, e0004013. [CrossRef] [PubMed]

75. Brown, K.; Leggat, P.A. Human Monkeypox: Current State of Knowledge and Implications for the Future. Trop. Med. Infect. Dis. 2016, 1, 8. [CrossRef] [PubMed]

76. Chermak, E.; Donato, R.; Lensink, M.F.; Petta, A.; Serra, L.; Scarno, V.; Cavallo, L.; Oliva, R. Introducing a Clus-tering Step in a Consensus Approach for the Scoring of Protein-Protein Docking Models. PLoS ONE 2016, 11, e0166460. [CrossRef] [PubMed]

77. Kennedy, J.S.; Gurwhit, M.; Dekker, C.L.; Frey, S.E.; Edwards, K.M.; Kenner, J.; Lock, M.; Empig, C.; Morikawa, S.; Saijo, M.; et al. Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults. J. Infect. Dis. 2011, 204, 1395–1402. [CrossRef] [PubMed]

78. Chen, J.N.; Deng, Y.; Huang, B.Y.; Han, D.; Wang, W.; Huang, M.J.; Zhai, C.C.; Zhao, Z.M.; Yang, R.; Zhao, Y.; et al. DNA Vaccines against Candida albicans. Sci. Rep. 2018, 8, 9. [CrossRef] [PubMed]

79. Sluder, A.E.; Paul, S.R.; Moise, L.; Dold, C.; Richard, G.; Silva-Reyes, L.; Baeten, L.A.; Scholzen, A.; Reeves, P.M.; Pollard, A.J.; et al. Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Infection. Front. Immunol. 2020, 11, 12397. [CrossRef] [PubMed]

80. Safavi, A.; Kefayat, A.; Sotoodehnejadmalalahi, F.; Salehi, M.; Modarressi, M.H. In Silico Analysis of Synap-tonomal Complex Protein 1 (SYCP1) and Acrosin Binding Protein (ACRBP) Antigens to Design Novel Multi-peptide Peptide Cancer Vaccine Against Breast Cancer. Int. J. Pept. Res. Ther. 2021, 27, 1343–1359. [CrossRef]

81. Sanami, S.; Azadegan-Dehkordi, F.; Rafieian-Kopaei, M.; Salehi, M.; Ghasemi-Dehnoo, M.; Mahooti, M.; Alizadeh, M.; Bagheri, N. Design of a multi-epitope vaccine candidate against cervical cancer using immunoinformatics approaches. Sci. Rep. 2021, 11, 12397. [CrossRef] [PubMed]

82. Shey, R.A.; Ghogomu, S.M.; Esoh, K.K.; Nebangwa, N.D.; Shintou, C.M.; Nongley, N.F.; Asa, B.F.; Ngale, F.N.; Vanhamme, L.; Souopgui, J. In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial dis-eases. Sci. Rep. 2019, 9, 4409. [CrossRef] [PubMed]

83. Tarang, S.; Keshwerani, V.; LaTendresse, B.; Lindgren, L.; Roche-Sanchez, S.M.; Weston, M.D. In silico Design of a Multivalent Vaccine against Candida albicans. Sci. Rep. 2020, 10, 1066. [CrossRef] [PubMed]

84. Soltan, M.A.; Eldeen, M.A.; Elbassiouny, N.; Kamel, H.L.; Abdelraheem, K.M.; Ab El-Gayyed, H.; Gouda, A.M.; Sheha, M.F.; Fayad, E.; Abu Ali, O.A.; et al. In Silico Designing of a Multitope Vaccine against Rhizopus microsporus with Potential Activity against Other Mucormycosis Causing Fungi. Cells 2021, 10, 3014. [CrossRef] [PubMed]

85. Akhtar, N.; Joshi, A.; Singh, J.; Kaushik, V. Design of a novel and potent multivalent epitope based human cyto-megalovirus peptide vaccine: An immunoinformatics approach. J. Mol. Liq. 2021, 335, 116586. [CrossRef]
86. Dar, H.A.; Ismail, S.; Waheed, Y.; Ahmad, S.; Jamil, Z.; Aziz, H.; Hetta, H.F.; Muhammad, K. Designing a multi-epitope vaccine against Mycobacteroides abscessus by pangenome-reverse vaccinology. Sci. Rep. 2021, 11, 11197. [CrossRef]
87. Kumar, P.; Lata, S.; Shankar, U.N.; Akif, M. Immunoinformatics-Based Designing of a Multi-Epitope Chimeric Vaccine From Multi-Domain Outer Surface Antigens of Leptospira. Front. Immunol. 2021, 12, 735373. [CrossRef] [PubMed]
88. Qamar, M.T.U.; Saleem, S.; Ashfaq, U.A.; Bari, A.; Anwar, F.; Alqahtani, S. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: An immune-informatics study. J. Transl. Med. 2019, 17, 362. [CrossRef]
89. Abdi, S.A.H.; Ali, A.; Sayed, S.F.; Abutahir Ali, A.; Alam, P. Multi-Epitope-Based Vaccine Candidate for Monkeypox: An In Silico Approach. Vaccines 2022, 10, 1564. [CrossRef] [PubMed]
90. Shantier, S.W.; Mustafa, M.I.; Abdelmoneim, A.H.; Fadl, H.A.; Elbager, S.G.; Makhawi, A.M. Novel multi epitope-based vaccine against monkeypox virus: Vaccinomic approach. Sci. Rep. 2022, 12, 15983. [CrossRef] [PubMed]
91. Aiman, S.; Alhamhoom, Y.; Ali, F.; Rahman, N.; Rastrelli, L.; Khan, A.; Farooq, Q.U.A.; Ahmed, A.; Khan, A.; Li, C. Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques- a bioinformatics and immunoinformatics approach. Front. Immunol. 2022, 13, 985450. [CrossRef]
92. Ullah, A.; Shahid, F.A.; Ul Haq, M.; ul Qamar, M.T.; Irfan, M.; Shaker, B.; Ahmad, S.; Alrumaihi, F.; Allemail, K.S.; Almattoudi, A. An integrative reverse vaccinology, immunoinformatic, docking and simulation approaches towards design-ign of multi-epitopes based vaccine against monkeypox virus. J. Biomol. Struct. Dyn. 2022, 1–14. [CrossRef]
93. Song, H.; Sidney, J.; Wiseman, R.W.; Josleyn, N.; Cohen, M.; E Blaney, J.; Jahrling, P.B.; Sette, A. Characterizing monkeypox virus specific CD8+ T cell epitopes in rhesus macaques. Virology 2013, 447, 181–186. [CrossRef] [PubMed]
94. Moise, L.; Buller, R.M.; Schriewer, J.; Lee, J.; Frey, S.E.; Weiner, D.B.; Martin, W.; De Groot, A.S. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011, 29, 501–511. [CrossRef]
95. Harrison, C. Monkeypox response relies on three vaccine suppliers. Nat. Biotechnol. 2022, 40, 1306–1307. [CrossRef]
96. Banerjee, N.; Mukhopadhyay, S. Viral glycoproteins: Biological role and application in diagnosis. Virus Dis. 2016, 27, 1–11. [CrossRef] [PubMed]
97. Kang, S.; Brown, H.M.; Hwang, S. Direct Antiviral Mechanisms of Interferon-Gamma. Immune Netw. 2018, 18, e33. [CrossRef]